Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Trends, and

Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Trends, and Forecast, 2022 - 2028

Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide.
Market Dynamics
Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.
Key features of the study:
This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics
The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressants and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Global Anti-Suicide Drugs Market, By Geography:
North America
U.S.
U.S. Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Canada
Canada Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Europe
U.K.
U.K Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Germany
Germany Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Italy
Italy Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
France
France Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Spain
Spain Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Russia
Russia Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Rest of Europe
Rest of Europe Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Asia-Pacific
China
China Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
India
India Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Japan
Japan Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
ASEAN
ASEAN Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Australia
Australia Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
South Korea
South Korea Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Rest of Asia Pacific (APAC)
Rest of Asia Pacific (APAC) Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Latin America
Brazil
Brazil Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Mexico
Mexico Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Argentina
Argentina Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Rest of Latin America
Rest of Latin America Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Middle East
GCC
GCC Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Israel
Israel Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Rest of Middle East
Rest of Middle East Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Africa
North Africa
North Africa Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Central Africa
Central Africa Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
South Africa
South Africa Anti-Suicide Drugs Market, By Drug Class:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
AstraZeneca plc
Eli Lilly and Company
Allergan plc
GlaxoSmithKline plc
Merck & Co., Inc.
H. Lundbeck A/S
NeuroRx, Inc.
Johnson & Johnson
“*” marked represents similar segmentation in other categories in the respective section.